Insight to CV Risks of CAR T-Cell Therapy

(MedPage Today) — More than 20% of adult patients who received chimeric antigen receptor (CAR) T-cell therapy had major cardiovascular events (MACE) in association with the innovative cancer therapy, a retrospective review showed.
The analysis…
Read More

Leave a Reply

%d bloggers like this: